unknown
Stage
2
Investors
About
ExcepGen develops RNA-based medicines that improve tolerability by modulating the innate immune response to nucleic acid vaccines using their RNAx platform technology.
Explore ExcepGen's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.